Aryl fused azapolycyclic compounds
AssigneePfizer Inc.
InventorsJotham Wadsworth Coe, Paige Roanne Palmer Brooks
Life of this patent
Estimating the term…
Abstract
Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.
Claims3
A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound comprising an amount of a compound of the formula
- wherein R19 is selected from the group consisting of hydrogen, (C1-C6)alkyl, or unconjugated (C3-C6)alkenyl, or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.
A method for treating a disorder or condition selected from spastic dystonia, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, pheochromocytoma, progressive supranuclear palsy;
- chemical dependencies and addictions;
- dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine;
- stroke, traumatic brain injury, obsessive-compulsive disorder, psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula
- wherein R19 is selected from the group consisting of hydrogen, (C1-C6)alkyl, or unconjugated (C3-C6)alkenyl, or a pharmaceutically acceptable salt thereof;
- that is effective in treating such disorder or condition.
Dependencies are inferred from the claim text.